文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

寒冷地区阿尔茨海默病临床早期血清学标志物与脑结构变化的研究

Study on Serological Markers and Brain Structural Changes in Early Clinical Stage of Alzheimer's Disease in Cold Regions.

作者信息

Yin Changhao, Chen Lingyu, Wang Jianhang, Zhao Weina

机构信息

Department of Neurology, Hongqi Hospital Affiliated to Mudanjiang Medical College, 157000 Mudanjiang, Heilongjiang, China.

Department of Neurology, Hongqi Hospital Affiliated to Mudanjiang Medical College, 157000 Mudanjiang, Heilongjiang, China; Center for Mudanjiang North Medicine Resource Development and Application Collaborative Innovation, 157000 Mudanjiang, Heilongjiang, China.

出版信息

Actas Esp Psiquiatr. 2025 Aug;53(4):669-682. doi: 10.62641/aep.v53i4.1936.


DOI:10.62641/aep.v53i4.1936
PMID:40791040
Abstract

BACKGROUND: Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) represent early clinical manifestations of Alzheimer's disease (AD). Recent research has highlighted serum markers and changes in brain structure as promising tools for diagnosing cerebral disorders. This study investigated serum biomarkers and brain structural changes in the early clinical stage of AD affected individuals residing in a cold region. METHODS: Clinical data from patients with SCD or MCI and from normal controls, who were tested at Hongqi Hospital Affiliated to Mudanjiang Medical College from January 2018 to December 2023, were retrospectively analysed. According to clinical classification, the patients were categorised into SCD (n = 60), MCI (n = 60) and normal control groups (n = 70). The magnetic resonance imaging data, serum levels of amyloid β 1-40/42, exosomal miRNA (34a/34c/135a) and apolipoprotein E (ApoE) genotype were collected and analysed. RESULTS: The mean diffusivity values in the bilateral parahippocampal gyrus, inferior longitudinal bundle, right inferior fronto-occipital tract and posterior cingulate gyrus in the SCD group decreased relative to those of the MCI group (all p < 0.05). Conversely, the fractional anisotropy values in the bilateral parahippocampal gyrus, inferior fronto-occipital tract, inferior longitudinal tract and posterior cingulate gyrus in the SCD group increased (all p < 0.05). Compared with the normal control group, the MCI and SCD groups showed elevated levels of serum Aβ1-40 and Aβ1-42 and exosomal miRNA-34a and miRNA-34c (all p < 0.05) and decreased exosomal miRNA-135a expression (p < 0.05). The serum levels of Aβ1-40, Aβ1-42 and exosomal miRNA-34a and miRNA-34c in the SCD group were lower than those in the MCI group (all p < 0.05), whereas miRNA-135a level was higher (p < 0.05). The proportions of ApoE ε3/3 in the normal control group was the highest (62.86%), and the proportions of ApoE ε2/4, ε3/4 and ε4/4 in the MCI group were the highest (38.33%, 26.67% and 10.00%, respectively). CONCLUSION: Changes in brain structure and serum biomarkers (miRNAs and Aβ) are evident in the early stages of AD, and the proportion of ApoE alleles vary in early AD. These findings may contribute to the development of an early recognition model for AD.

摘要

背景:主观认知下降(SCD)和轻度认知障碍(MCI)是阿尔茨海默病(AD)的早期临床表现。最近的研究强调血清标志物和脑结构变化是诊断脑部疾病的有前景的工具。本研究调查了居住在寒冷地区的AD患者早期临床阶段的血清生物标志物和脑结构变化。 方法:回顾性分析2018年1月至2023年12月在牡丹江医学院附属红旗医院接受检测的SCD或MCI患者及正常对照的临床资料。根据临床分类,将患者分为SCD组(n = 60)、MCI组(n = 60)和正常对照组(n = 70)。收集并分析磁共振成像数据、血清淀粉样蛋白β1-40/42水平、外泌体微小RNA(34a/34c/135a)和载脂蛋白E(ApoE)基因型。 结果:SCD组双侧海马旁回、下纵束、右侧额枕下束和后扣带回的平均扩散率值相对于MCI组降低(均p < 0.05)。相反,SCD组双侧海马旁回、额枕下束、下纵束和后扣带回的各向异性分数值升高(均p < 0.05)。与正常对照组相比,MCI组和SCD组血清Aβ1-40和Aβ1-42水平以及外泌体miRNA-34a和miRNA-34c水平升高(均p < 0.05),外泌体miRNA-135a表达降低(p < 0.05)。SCD组血清Aβ1-40、Aβ1-42水平以及外泌体miRNA-34a和miRNA-34c水平低于MCI组(均p < 0.05),而miRNA-135a水平更高(p < 0.05)。正常对照组中ApoE ε3/3的比例最高(62.86%),MCI组中ApoE ε2/4、ε3/4和ε4/4的比例最高(分别为38.33%、26.67%和10.00%)。 结论:AD早期脑结构和血清生物标志物(微小RNA和Aβ)发生变化,且ApoE等位基因比例在AD早期有所不同。这些发现可能有助于AD早期识别模型的建立。

相似文献

[1]
Study on Serological Markers and Brain Structural Changes in Early Clinical Stage of Alzheimer's Disease in Cold Regions.

Actas Esp Psiquiatr. 2025-8

[2]
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2014-6-10

[3]
Predicting cognitive decline: Deep-learning reveals subtle brain changes in pre-MCI stage.

J Prev Alzheimers Dis. 2025-5

[4]
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2017-3-22

[5]
Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer's disease.

Fluids Barriers CNS. 2025-1-9

[6]
Subjective Cognitive Decline Plus and Longitudinal Assessment and Risk for Cognitive Impairment.

JAMA Psychiatry. 2024-10-1

[7]
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.

Alzheimers Res Ther. 2025-2-19

[8]
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.

JAMA Netw Open. 2025-7-1

[9]
Cerebral perfusion correlates with amyloid deposition in patients with mild cognitive impairment due to Alzheimer's disease.

J Prev Alzheimers Dis. 2025-2

[10]
Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients.

J Neurochem. 2025-8

本文引用的文献

[1]
Patterns and trends in the burden of Alzheimer's disease and related dementias in China (1990-2021) and predictions to 2040.

J Alzheimers Dis. 2025-6

[2]
Extreme Heat and Hospitalization Among Older Persons With Alzheimer Disease and Related Dementias.

JAMA Intern Med. 2025-4-1

[3]
Exosomal MicroRNAs in Alzheimer's Disease: Unveiling Their Role and Pioneering Tools for Diagnosis and Treatment.

J Clin Med. 2024-11-19

[4]
ApoE Gene Polymorphism and Clinical, Biochemical, and Sociodemographic Characteristics of Alzheimer's Disease Patients From Northern and Southern Regions of Kazakhstan.

Int J Geriatr Psychiatry. 2024-11

[5]
Transition of mild cognitive impairment to Alzheimer's disease: Medications as modifiable risk factors.

PLoS One. 2024

[6]
The duality of amyloid-β: its role in normal and Alzheimer's disease states.

Mol Brain. 2024-7-17

[7]
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease.

Aging Dis. 2024-4-24

[8]
APOEε4 Carriers Exhibit Objective Cognitive Deficits: A Cross-Sectional Study in a Single Center Trial.

Brain Sci. 2024-3-15

[9]
Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management.

J Control Release. 2024-3

[10]
MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential.

Cancers (Basel). 2023-9-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索